All translations

Enter a message name below to show all available translations.

Found 2 translations.

Name	Current message text
^h English (en)	Dapagliflozin disposition is not evidently affected by BMI or [[body weight]], therefore the pharmacokinetic findings are expected to be applicable to patients with a higher [[Body mass index\|BMI]]. Dapagliflozin resulted in [[dose-dependent]] increases excretions in urinary glucose, up to 47g/d following single-dose administration, which can be expected from its [[mechanism of action]], dapagliflozin.
^h Japanese (ja)	ダパグリフロジンの体内動態はBMIや[[body weight/ja\|体重]]に明らかに影響されないため、薬物動態学的知見は[[Body mass index/ja\|BMI]]の高い患者にも適用できると予想される。ダパグリフロジンの[[mechanism of action/ja\|作用機序]]から予想されるように、ダパグリフロジンは[[dose-dependent/ja\|用量依存的]]に尿中グルコース排泄量を増加させ、単回投与で最大47g/dであった。